Revive Therapeutics (TSE:RVV) has released an update.
Revive Therapeutics has updated stakeholders on the progress of their lateral flow test kit for detecting long COVID, following guidance from the FDA to pursue a De Novo regulatory pathway, which requires a clinical study for potential approval. As there’s no FDA-approved clinical diagnosis for long COVID yet, the company has secured exclusive rights to novel blood biomarkers for the condition, aiming to address a critical need in post-COVID-19 healthcare.
For further insights into TSE:RVV stock, check out TipRanks’ Stock Analysis page.
